Sunlenca
Oral Bridging of Lenacapavir Maintains Viral Suppression Among HIV Patients
Oral bridging of lenacapavir enabled patients to maintain viral suppression of their HIV after missed doses of ...
JULY 26, 2023
FDA Approves Sunlenca for Adults With Resistant HIV
The FDA approved lenacapavir, a first-in-class, long-acting HIV capsid inhibitor, which is injected twice ...
DECEMBER 22, 2022
Load more